Match Document Document Title
6884808 Heterocycle-containing carboxylic acid derivative and drug containing the same  
Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): wherein A represents, for example, a heteroaryl group which contains at least one...
6878714 Substituted alkylamine derivatives and methods of use  
Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically...
6875769 Substituted6,6-hetero-bicyclicderivatives  
This invention relates to compounds of the formula wherein A, B, D, E, K, G, R3 and R5 are defined as in the specification, and to the pharmaceutically acceptable salts of such compounds.
6872730 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists  
The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their...
6869945 Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes  
This application is directed to compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic...
6861434 Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one  
Compounds of the formula: useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced...
6861436 1-glyoxylamide indolizines for treating cancer  
Disclosed is a compound represented by Structural Formula (I): Ring A is substituted or unsubstituted and optionally fused to an aryl group.Z1 and Z2 are independently ═O, ═S, ═N—OR12 or ═NR12 R1...
6852733 Sodium-hydrogen exchanger type 1 inhibitor  
NHE-1 inhibitor, methods of using the NHE-1 inhibitor and pharmaceutical compositions containing the NHE-1 inhibitor. The NHE-1 inhibitor is useful for the reduction of tissue damage resulting...
6849639 Integrin inhibitors and their methods of use  
The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions...
6844346 Chromogenic substrates of sialidase and methods of making and using the same  
The subject invention discloses materials and methods for the design, synthesis, and biochemical evaluation of chromogenic substrate compounds for sialidases of bacterial, viral, protozoa, and...
6844357 Substituted quinolin-2-one derivatives useful as antiproliferative agents  
The present invention relates to compounds of formulas 1 and 2 wherein R1, R2, R4, R5, R6, R7, R8, R10 and Z are as defined herein. The present invention also relates to pharmaceutical...
6844344 Benzofuran derivatives  
The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of...
6841562 Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor  
Quinolylpropylpiperidine derivatives of general formula (I) in which R1a is hydrogen, halogen, hydroxyl, amino, alkylamino, dialkylamino, hydroxyamino, alkoxyamino or alkylalkoxyamino and R1b is...
6838468 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders  
Compounds of general formula I[Chemical formula should be inserted here. Please see paper copy] R1 is selected from any one of phenyl, pyridinyl, pyrrolyl, thienyl, furanyl, imidazolyl, triazolyl,...
6831089 Muscarinic antagonists  
The present invention discloses compounds, which are novel muscarinic receptor antagonists, as well as methods for preparing such compounds. In another embodiment, the invention discloses...
6825215 1,1-disubstituted cyclic inhibitors of matrix metalloproteases and TNF-α  
The present application describes novel 1,1-disubsituted cyclic derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring...
6821988 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases  
This invention provides compounds of Formula (I), represented by the structure wherein G1, G2, G3, G4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful...
6815451 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists  
The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical...
6809097 Quinoline derivatives inhibiting the effect of growth factors such as VEGF  
Compounds of the formula (I): wherein: R2 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents...
6809106 Quinoline derivatives as inhibitors of MEK enzymes  
A compound of formula (I) or a pharmaceutically acceptable salt thereof; for use as a medicament wherein:n is 0-1;Y is selected from —NH—, —O—, —S—, or —NR7— where R7 is alkyl of 1-6 carbon...
6809093 2-substituted heterocyclic compounds  
Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds. An example compound has the formula:
6809107 Neurotrophic pyrrolidines and piperidines, and related compositions and methods  
This invention provides compounds having the following general structures: This invention also provides pharmaceutical compositions comprising same and methods of using these compositions to treat...
6806279 Small-molecule inhibitors of interleukin-2  
Compounds of formulae I and I′, methods of making them, pharmaceutical compositions containing them, and methods for their use. The compounds are antagonists of IL-2/IL-2R binding; and are useful...
6806277 Quinolylpropylpiperidine derivatives, preparation process and intermediates, and compositions including them  
Quinolylpropylpiperidine derivatives of general formula (I) in which: R1 is NH2, alkylamino, dialkylamino, hydroxyamino, alkyl(alkyloxy)amino or alkyloxyamino,R2 is a carboxyl, carboxymethyl or...
6803369 Compounds and methods for the treatment of neoplastic disease  
A method of modulating the activity of a aberrant cell topoisomerase enzyme involving contacting the enzyme with a compound that inhibits enzyme-mediated cleavage of a polynucleotide substrate...
6784190 Integrin receptor antagonists  
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are...
6784167 17-beta-hydroxysteroid dehydrogenase-II inhibitors  
17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R4)(R6)Y are oriented cis to each other; W represents O or S;...
6784184 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase  
This invention relates to a method of using novel 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar′, R6, m and n are as defined in...
6780875 Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists  
A compound, or a solvate or a salt thereof, of formula (I): wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted C5-7 cycloalkyl group, or an...
6777427 Tetrahydroquinoline compounds  
Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have...
6770648 Compounds for the modulation of PPAR&ggr activity  
Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
6756370 Piperidine alcohols  
The invention relates to compounds of formula (I), wherein R1, R2 and A have the meanings given in claim 1, are potent 5-HT2A antagonists and are suitable for treating psychoses, schizophrenia,...
6753334 Preparation of sodium-hydrogen exchanger type-1 inhibitors  
This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ intermediates of the NHE-1 inhibitors and a new almost colorless form of the NHE-1...
6753335 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain  
Compounds of general formula I R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, and triazolyl;where each R1 phenyl ring and R1 heteroaromatic ring may optionally and...
6747050 Isoxazoline derivative and a process for the preparation thereof  
The present invention provides to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative...
6743807 Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α  
The present application describes novel cyclic β-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing...
6743804 Quinoline derivatives as NK3 antagonists  
The present invention relates to a novel use, in particular a novel pharmaceutical use for a series of quinoline derivatives.
6740666 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors  
Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl...
6740649 Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)  
The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2...
6713489 7-&lsqb (4′-trifluoromethyl-biphenyl-2-carbonyl)amino&rsqb -quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B  
This invention relates to compounds of Formula I: that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or...
6710033 Methods and treatment of multiple sclerosis  
The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in...
6706757 Chroman derivatives as 5-hydroxytryptamine-6 ligands  
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
6696488 (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production  
Novel (hydroxyethyl)ureas are described. These compounds are effective inhibitors of certain aspartyl proteases, notably secretases involved in the enzymatic cleavage of amyloid precursor protein...
6696459 Steroid receptor modulator compounds and methods  
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds,...
6696437 Heterocyclically substituted benzimidazoles, the production and application thereof  
The present invention relates to novel benzimidazoles, their preparation and their use as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30) for producing drugs.
6689792 Antipsychotic indolyl derivatives  
Compounds of formula (1) are provided: whereinR1 and R2 are H, OH, F, Cl, Br, I, 1 to 6 carbon alkyl or alkenyl, 1 to 6 carbon alkoxy, aryl, OR5, nitro, amino, CF3 or R1 and R2 are taken together...
6689772 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors  
This invention provides compounds of Formula (I), having the structure where T, Z, X, A, R1, R2a, R2b, R2c, R3, R4, and n are defined herein, or a pharmaceutically acceptable salt thereof which...
6686388 Regulators of the hedgehog pathway, compositions and uses related thereto  
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function...
6683092 &lsqb 3-(C5-14ALKYL-2-OXO-1,2,3,4-TETRAHYDRO-QUINOLIN-6-YL)-3-OXO-PROPENYL&rsqb -PHENYL AND &lsqb 3-(C5-14ALKYL-2-OXO-1,2,3,4- TETRAHYDRO-QUINOLIN-6-YL)-3-OXO-PROPENYL&rsqb -HETEROARYL DERIVATIVES HAVING ANTI-TUMOR ACTIVITY  
Compounds of the formula where the variables have the meaning defined in the specification have anti-tumor activity.
6683079 3-(amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases  
3-(amino- or aminoalkyl) pyridinone derivatives having the formula (1) wherein Q, X, Y, and R3-R6 are as defined, which derivatives are useful for the treatment of HIV related diseases.